medigraphic.com

2010, Number 3

<< Back Next >>

Rev Hosp Jua Mex 2010; 77 (3)

Seguridad y eficacia del uso de metilprednisolona en la lesión medular espinal aguda: Revisión sistematizada de la literatura

García SA, Pérez CRS, Márquez GEA, Argoty TP

Language: Spanish
References: 44
Page: 187-207
PDF size: 325.45 Kb.


ABSTRACT

Acute Spinal Cord Injury (LMEA), is potentially devastating with high rates of morbidity and mortality and affects mainly the socioeconomic population that is active. It has been proposed as a treatment strategy using Methylprednisolone Sodium Succinate (SSMP) in high doses, because it is a potent anti-inflammatory drug for quick action. For this reason, we performed a systematic review of the use of Methylprednisolone Sodium Succinate in LMEA with the aim of reviewing the effectiveness and safety of using high doses of SSMP. They are used as sources of information the National Library of Medicine and the National Institutes of Health United States, the Cochrane Library. The results were submitted to the kappa statistic (κ), and focus on tables according to the level of significance of each.


REFERENCES

  1. Baptiste DC, Fehlings MG. Pharmacological approaches to repair the injured spinal cord. J Neurotrauma 2006; 23: 318-34.

  2. Kwon BK, Tetzlaff W, Grauer JN, Beiner J, Vaccaro AR. Pathophysiology and pharmacologic treatment of acute spinal cord injury. The Spine J 2004; 4: 451-64.

  3. Kubeck JP, Merola A, Mathur S, Brkaric M, Majid K, et al. End organ effects of high-dose human equivalent methylprednisolone in a spinal cord injury rat model. Spine 2006; 31: 257-61.

  4. Eck J, Nachtigall D, Humphreys C, Hodges SD. Questionnaire survey of spine surgeons on the use of methylprednisolone for acute spinal cord injury. Spine 2006; 31: E250-3.

  5. Sekhon LH, Fehlings MG. Epidemiology, Demographics, and Pathophysiology of Acute Spinal Cord Injury. Spine 2001 (26); 24S: 2-12.

  6. Tator CH, Fehlings MG. Review of the secondary injury theory of acute spinal cord trauma with emphasis on vascular mechanisms. J Neurosurg 1991; 75: 15-26.

  7. Tator CH. Update on the pathophysiology and pathology of acute spinal cord injury. Brain Pathol 1995; 5: 407-13.

  8. Fehlings MG. Summary statement: The use of methylprednisolone in acute spinal cord injury. Spine 2001; 26: S55.

  9. Agrawal SK, Fehlings MG. Mechanisms of secondary injury to spinal cord axons in vitro: Role of Na, Na-K-ATPase, the Na-H exchanger, and the Na-Ca exchanger. J Neurosci 1996; 16: 545-52.

  10. Agrawal SK, Fehlings MG. The role of NMDA and non-NMDA ionotropic glutamate receptors in traumatic spinal cord axonal injury. J Neurosci 1997; 17: 1055-63.

  11. Koyanagi I, Tator CH, Lea PJ. Three-dimensional analysis of the vascular system in the rat spinal cord with scanning electron microscopy of vascular corrosion casts: 2. Acute spinal cord injury. Neurosurgery 1993; 33: 285-92.

  12. Amar AP, Levy ML. Pathogenesis and pharmacological strategies for mitigating secondary damage in acute spinal cord injury. Neurosurgery 1999; 44: 1027-39.

  13. Apuzzo MLJ. Pharmacological therapy after acute cervical spinal cord injury. Neurosurgery 2002; 50: S63-72

  14. Braken MB, Collins WF, Freeman DF, Shepard MJ, Wagner FW, Silten RM, et al. Efficacy of methylprednisolone in acute spinal cord injury. JAMA 1984; 251: 45-52.

  15. Bracken MB, Shepard MJ, Collins WF, et al. A randomized, contolled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury: Results of the second national acute spinal cord injury study. N Engl J Med 1990; 322: 1405-11.

  16. Bracken MB, Shepard MJ, Holford TR, et al. Administration or methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury: Results of the third national acute spinal cord injury randomized controlled trial. National acute spinal cord injury study. JAMA 1997; 277: 1597-604.

  17. Bracken MB, Shepard MJ, Collins WF Jr, Holford TR, Baskin DS, Eisenberg HM, et al. Methylprednisolone or naloxone treatment after acute spinal cord injury: 1-year follow-up data. Results of the second national acute spinal cord injury study. J Neurosurg 1992; 76: 23-31.

  18. Rabchevsky AG, Fugaccia I, Sullivan PG, Blades DA, Scheff SW. Efficacy or Methylprednisolone therapy for the injured rat spinal cord. J Neuroscience Research 2002; 68: 7-18.

  19. Hugenholtz H, Methylprednisolone for acute spinal cord injury: not a standard of care. CMAJ 2003; 9: 168.

  20. Gerndt SJ, Rodríguez JL, Pawlik JW, et al, Consequences of high-dose steroid therapy for acute spinal cord injury. J Trauma 1997; 42: 279-84.

  21. Matsumoto T, Tamaki T, Kawakami M, et al. Early complications of high-dose methylprednisolone sodium succinate treatment in the follow-up of acute cervical spinal cord injury. Spine 2001; 26: 426-30.

  22. Pollard ME, Apple DF. Factors associated with improved neurologic out-comes in patients with incomplete tetraplegia. Spine 2003; 28: 33-9.

  23. Ito Y, Sugimoto Y, Tomioka M, Kai N, Tanaka M. Does high dose methylprednisolone sodium succinate really improve neurological status in patient with acute cervical cord injury? Spine 2009; 34: 2121-4.

  24. Hall ED. Drug development in spinal cord injury: what is the FDA looking for? J Rehabil Res Rev 2003; 40: S80-S92.

  25. Hurlbert RJ, Moulton R. Why do you prescribe methylprednisolone for acute spinal cord injury? A Canadian perspective and a position statement. Can J Neurol Sci 2002; 29: 236-9.

  26. Molloy S, Price M, Casey TH. Questionnaire survey of the views of the delegates at the European cervical spine research society meeting on administration of methylpresnisolone for acute traumatic spinal cord injury. Spine 2001; 26: E562-4.

  27. Coleman WP, Benzel E, Cahill DW, et al. A Critical Appraisal of the Reporting of the National Acute Spinal Cord Injury Studies (II and III) of Methylprednisolone in Acute Spinal Cord Injury. J Spinal Disorders 2000; 13: 185-99.

  28. Bracken MB, Shepard MJ, Hellenbrand KG, Collins WF, Leosummers L, et al. Methylprednisolone and neurological function 1 year after spinal cord injury. J Neurosurg 1985; 63: 704-13.

  29. George ER, Scholten DJ, Buechler CM, Jordan-Tibbs J, Mattice C, Albrecht RM. Failure of Methylprednisolone to improve the outcome of spinal cord injuries. Am surg 1995; 61: 659-64.

  30. Poynton AR, O´Farrell DA, Shannon F, Murray P, McManus F, Walsh MG. An evaluation of the factors affecting neurological recovery following spinal cord injury. Injury 1997; 28: 545-8.

  31. Bracken MB, Shepard MJ, Holford TR, et al. Methylprednisolone or tirilazad mesylate administration after acute spinal cord injury: 1–year follow up. Results of the third national cute spinal cord injury randomized controlled trial. J Neurosurg 1998; 89: 699-706.

  32. Pointillart V, Petitjean ME, Wiart L, Vital JM, Lassie P, Thicoipe M. Pharmacological therapy of spinal cord injury during the acute phase. Spinal Cord 2000; 38: 71-6.

  33. Tsutsumi S, Ueta T, Shiba K, Yamamoto S, Takagishi K. Effects of the Second National Acute Spinal Cord injury study of High- Dose Methylprednisolone therapy on acute cervical spinal cord injury- Results in spinal injuries center. Spine 2006; 31(26): 2992-6.

  34. Lee HC, Cho DY, Lee WY, Chuang HC. Pitfalls in treatment of acute cervical spinal cord injury using high-dose Methylprednisolone: a retrospect audit of 111 patients. Surgical Neurology 2007; 68 S1: 37-42.

  35. Ito Y, Sugimoto Y, Tomioka M, Kai N, Tanaka M. Does high dose Methylprednisolone sodium succinate really improve neurological status in patient with acute cervical cord injury? Spine 2009; 34(20): 2121-4.

  36. Hulbert J. The rol of steroids in acute spinal cord injury. Spine 2001; 26 (24S): 39-46.

  37. Miller S. Methylprednisolone in acute spinal cord injury: a tarnished standard. J Neurosurg Anesthesiol 2008; 20(29): 140-2.

  38. Nesathurai S. Steroids and spinal cord injury: revisiting NASCIS 2 and NASCIS 3 trials. J Trauma 1998: 45: 1088-93.

  39. Coleman WP, Benzel D, Cahill WD, et al. A critical appraisal of reporting of national acute spinal cord injury studies (II and III) methylprednisolone in acute spinal cord injury. J Spinal Disord 2000; 13: 185-9.

  40. Hulbert RJ. Methylprednisolone for acute spinal cord injury: an inappropriate standard of care. J Neurosurg 2000; 93: 1-7.

  41. Hugenholtz H. Methylprednisolone for acute spinal cord injury: not a standard of care. CMAJ 2003; 29: 168-9.

  42. Hulbert J. Strategies of medical intervention in management of acute spinal cord injury. Spine 2006; 31(S11): 16-21.

  43. Hulbert RJ, MoultonR. Why do you prescribe methylprednisolone for acute spinal cord injury? Can Neurol Sci 2002; 29: 236-9.

  44. Woolf SH. Assessing the effectiveness of preventive maneuers: analytic principles and systematic methods in reviewing evidence and developing clinical practice recommendations. J Clin Epidemiol 1990; 43: 891-905.




2020     |     www.medigraphic.com